Granules India advances as USFDA completes inspection at its Gagillapur facility

17 Oct 2016 Evaluate

Granules India is currently trading at Rs. 121.95, up by 1.95 points or 1.63% from its previous closing of Rs. 120.00 on the BSE.

The scrip opened at Rs. 123.35 and has touched a high and low of Rs. 125.60 and Rs. 121.20 respectively. So far 3,64,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 164.45 on 01-Dec-2015 and a 52 week low of Rs. 101.25 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 125.60 and Rs. 117.75 respectively. The current market cap of the company is Rs. 2,648.29 crore.

The promoters holding in the company stood at 51.04%, while Institutions and Non-Institutions held 9.09% and 39.87% respectively.

Granules India’s Gagillapur facility located at Hyderabad in state of Telangana, has successfully completed US Food and Drug Administration (USFDA) inspection without any observations. This facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

The company has recently received approval from USFDA for anti-inflammatory drug Ibuprofen tablets in the US market. The regulator has approved Abbreviated New Drug Application (ANDA) for Ibuprofen tablets USP, 200 mg (OTC) filed by the pharma major.

Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.


Granules India Share Price

593.90 -12.00 (-1.98%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.